Navigation Links
Accel-KKR Makes Growth Equity Investment in Zinc Ahead, Leading Provider of Marketing Compliance Solutions for the Life Sciences Industry
Date:6/21/2013

MENLO PARK, Calif. and OXFORD, England, June 21, 2013 /PRNewswire/ -- Accel-KKR, a technology-focused private equity investment firm, today announced it has made a growth equity investment in Zinc Ahead, the world's leading provider of marketing compliance solutions for the life sciences industry.  Terms of the investment were not disclosed. 

Zinc Ahead's flagship product, Zinc MAPS, is now used by more than 100 life sciences companies in over 160 countries worldwide, and is widely regarded as the gold standard in marketing compliance solutions in the life sciences industry.  The company was founded by James Brown and Zoe Cottrell in 2001.

Accel-KKR Managing Director Greg Williams commented about the investment: "We are excited to partner with James Brown and Zoe Cottrell and the Zinc Ahead team as they continue to execute the growth plan that has established the company as a market leader in life sciences marketing compliance solutions.  This investment fits very well with our focus on investing in and supporting market leading software and technology-enabled service businesses."

James Brown, CEO and co-founder of Zinc Ahead, said: "Over the past dozen years, our company has generated strong growth as we have established Zinc MAPS as the gold standard marketing compliance solution designed specifically for the life sciences industry.  The investment from Accel-KKR will enable Zinc to continue its growth on a global scale, especially in North America.  Accel-KKR team has deep knowledge of software and extensive experience investing alongside founder-led management teams, and they will be a tremendous partner as we grow."

Accel-KKR Managing Director Tom Barnds said: "Accel-KKR's investment in Zinc Ahead represents our tenth investment in European software and IT-enabled businesses and underscores our increased commitment to this market.  In Europe, we are focused on partnering with growing, often founder-led, technology companies, an investment strategy that has distinguished Accel-KKR over the past decade in the U.S."About Zinc AheadCommitted to innovation and product excellence, Zinc Ahead is the world's leading provider of marketing compliance solutions designed specifically for the life sciences industry.

The company's flagship product, Zinc MAPS has already transformed compliance processes in more than 100 life sciences companies worldwide (http://www.zinc-ahead.com/Clients/Clients), demonstrating rapid efficiency and cost savings.

Founded in 2001, Zinc Ahead is a privately-held company with headquarters in Oxford, UK, and offices in New York and Sydney, Australia.  The company's 85 employees are dedicated to providing excellent customer service and support to the 30,000 daily Zinc MAPS users in over 160 countries worldwide.  For more information please visit www.zinc-ahead.com

About Accel-KKRAccel-KKR is a technology-focused private equity firm with over $2.3 billion in assets under management.  The firm invests primarily in software and IT-enabled businesses well positioned for top-line and bottom-line growth.  At the core of Accel-KKR's investment strategy is a commitment to developing strong partnerships with the management teams of its portfolio companies and a focus on building value through significant resources available through the Accel-KKR network.  Accel-KKR focuses on middle market companies and provides a broad range of capital solutions from minority growth investments to buyouts, recapitalizations, divisional carveouts and going-private transactions.  For more information, please visit www.accel-kkr.com.Contact:

Todd FogartyKekst and Company212-521-4854todd-fogarty@kekst.com


'/>"/>
SOURCE Accel-KKR
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
2. The Lancet Makes Research More Accessible for Healthcare Professionals With New App for iPad
3. GeNO LLC Makes Significant Additions to Management Team to Increase Capability and Talent
4. Oracle chairman Jeff Henley makes $50 million gift to UC Santa Barbara
5. Foundation Venture Capital Group Makes Eighth Start-Up Investment
6. Infectious Disease Prevalence and New Strains Appearing Each Year Makes a Watertight Case for Clinical Laboratory Testing, Finds Frost & Sullivan
7. Chemical makes blind mice see; compound holds promise for treating humans
8. Mass spec makes the clinical grade
9. Metabolic engineer synthesizes key breast milk ingredient, makes research possible
10. Lava dots: Rice makes hollow, soft-shelled quantum dots
11. Alpha Source, Inc. Makes Third Straight Inc. 5000 List with Three-Year Sales Growth of 53%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... Feb. 3, 2016  With the growing need ... that is underway, therapies such as monoclonal antibodies, ... whole host of indications are in high demand. ... the development and production of these therapeutics. However, ... and high costs, novel approaches and novel expression ...
(Date:2/3/2016)... 2016 New Jersey Health Foundation (NJHF) has ... for researchers in New Jersey ... demonstrates exciting potential.   James M. ... New Jersey Health Foundation Research Grant Program ... institutions— Princeton University, Rutgers University, Rowan University and ...
(Date:2/3/2016)... , ... February 03, 2016 , ... ... Linux and Unix visualization solutions today announced the addition of a powerful “Session ... users to see the current state of the remote Linux desktop or other ...
(Date:2/3/2016)... 2016  Today, Symphony Technology Group (STG) announced the ... leading provider of primary research and analytics-based insight for ... , a global information and technology services company serving ... will be integrated into IMS Health to form a ... capabilities. ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):